We are excited to announce that our major article, “NANOSPRESSO: Towards personalized locally produced nucleic acid nanomedicines,” has just been published in the widely read journal Frontiers in Science!

A groundbreaking vision for rare diseases

The NANOSPRESSO concept is set to revolutionize how we approach the treatment of rare diseases. By leveraging advanced nucleic acid therapeutics and lipid nanoparticles, this new model empowers local hospital pharmacies to craft personalized, high-quality nanomedicines tailored specifically to individual patient needs, directly at the point of care.

Why is NANOSPRESSO important?

• Addressing the rare disease treatment gap: Traditional pharmaceutical manufacturing is centralized and optimized for large-scale production, leaving rare diseases underserved due to economic and logistical barriers.
• Democratizing personalized medicine: NANOSPRESSO’s compact, cartridge-based microfluidic technology brings affordable, precision healthcare closer to patients—even in resource-limited settings.
• A versatile platform: This innovation can potentially extend beyond rare diseases to other precision medicine applications such as personalized cancer therapies and rapid-response vaccines.

Read the full article

Discover our complete vision, detailed methodology, and ambitious plans for NANOSPRESSO. Read the full article here: Frontiers in Science Article Link.

What You Will Learn

• Comprehensive review of nucleic acid therapeutics and their potential for precision medicine.
• Description of the technological, biological, medical, and regulatory challenges associated with local nanomedicine production.
• Strategic roadmap for integrating NANOSPRESSO into clinical practice.

5 Unique Insights from the NANOSPRESSO Article:

1. Pharmacy Compounding Reimagined: NANOSPRESSO aims at revitalizing the traditional pharmacy practice of compounding through the integration of cutting-edge microfluidics, positioning pharmacists as key players in future personalized therapies.
2. Towards Sustainable Healthcare: By proposing decentralized drug production, NANOSPRESSO seeks to significantly reduce the environmental impact and resource use typically associated with conventional drug manufacturing and global distribution.
3. Simplifying Cold Chain Logistics: The proposed local, on-site production model could help reduce reliance on complex and costly cold-chain logistics, potentially making advanced nanomedicines feasible in remote or resource-limited hospitals.
4. Exploring Tailored Regulatory Pathways: The project emphasizes exploring new regulatory approaches that might specifically accommodate individualized drug manufacturing, encouraging essential discussions among scientists, regulators, and policymakers.
5. Potential for Real-Time Adaptability: The modular concept of NANOSPRESSO aims to allow hospitals to swiftly adapt therapies to emerging healthcare challenges, such as infectious outbreaks or rapidly evolving cancer treatments, suggesting a promising direction for responsive healthcare.

About the Authors

This article was led by Dr. Mariona Estapé Senti, a researcher specializing in advanced nanomedicine solutions at University Medical Center Utrecht, with critical contributions from Nanospresso experts from the European Technology Platform Nanomedicine, CureVac, University of Oxford, Karolinska Institutet, and SINTEF Industry. The multidisciplinary team is dedicated to addressing the unmet medical needs of patients with rare diseases.

Follow NANOSPRESSO

Stay updated with all the latest news, events, and developments by following our LinkedIn page:

Follow NANOSPRESSO on LinkedIn

We warmly thank our exceptional consortium members and Frontiers in Science for their outstanding collaboration and support in this exciting journey toward accessible personalized nanomedicines.